Evaluation of Cardiotoxicity in HER-2 Positive Breast Cancer Patients Treated With Radiation Therapy and Trastuzumab

被引：0
|
作者：
Bachir, B. [1 ]
Anouti, S. [1 ]
Jaoude, J. Abi [1 ]
Kayali, M. [1 ]
Tfayli, A. [1 ]
De Azambuja, E. [2 ]
Poortmans, P. [3 ]
Zeidan, Y. [1 ,4 ]
机构：
[1] Amer Univ Beirut, Med Ctr, Beirut, Lebanon
[2] ULB, Brussels, Belgium
[3] Iridium Kankernetwerk, Dept Radiat Oncol, Antwerp, Belgium
[4] Baptist Hlth South Florida, Lynn Canc Inst, Boca Raton, FL USA
来源：
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS | 2021年 / 111卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
12
引用
收藏
页码：S7 / S7
页数：1
相关论文
共 50 条
  • [21] Acute Toxicity in Patients With HER2-Positive Breast Cancer Treated With Adjuvant Radiation Therapy and Concurrent Trastuzumab and Pertuzumab
    Spiegel, D.
    Marcom, K.
    Peterson, B.
    Force, J.
    Howie, L.
    Palta, M.
    Blitzblau, R. C.
    Horton, J. K., Sr.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2016, 96 (02): : E9 - E10
  • [22] Cost-effectiveness analysis of trastuzumab therapy in patients with early HER-2 positive breast cancer in Brazil
    Vernaglia, P. R.
    Cunha, F. M.
    Correa, M.
    Perdicaris, M. R.
    Saggia, M. G.
    Santos, E. A., V
    Nasciben, V. D.
    Pelizon, C.
    BREAST CANCER RESEARCH AND TREATMENT, 2007, 106 : S106 - S106
  • [23] HER-2 positive breast cancer and trastuzumab: lessons learnt by heart
    Outhoff, k
    SOUTHERN AFRICAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY, 2009, 1 (02) : 52 - 57
  • [24] Cardiotoxicity of trastuzumab in patients with HER2-positive gastric cancer
    Park, Ji Soo
    Youn, Jong-Chan
    Shim, Chi Young
    Hong, Geu-Ru
    Lee, Choong-Kun
    Kim, Jee Hyung
    Park, Hyung Soon
    Heo, Su Jin
    Beom, Seung Hoon
    Kim, Hyo Song
    Rha, Sun Young
    Chung, Hyun Cheol
    Kang, Seok-Min
    Jung, Minkyu
    ONCOTARGET, 2017, 8 (37) : 61837 - 61845
  • [25] Docetaxel in the adjuvant therapy of HER-2 positive breast cancer patients
    Vici, P.
    Viola, G.
    Botti, C.
    Rossi, S.
    Vitucci, C.
    Corsetti, S.
    Di Lauro, L.
    Sergi, D.
    Foggi, P.
    Perri, P.
    Tirellil, C.
    Mottolese, M.
    Fattoruso, S. I. S.
    Lopez, M.
    CLINICA TERAPEUTICA, 2008, 159 (06): : 449 - 452
  • [26] HER-2 positive breast cancer: what else beyond trastuzumab-based therapy?
    Widakowich, Christian
    Dinh, Phuong
    de Azambuja, Evandro
    Awada, Ahmad
    Piccart-Gebhart, Martine
    ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY, 2008, 8 (05) : 488 - 496
  • [27] Cardiotoxicity of trastuzumab adjuvant treatment in positive HER2 breast cancer
    Piotrowski, G.
    Gawor, R.
    Potemski, P.
    Gawor, Z.
    EUROPEAN HEART JOURNAL, 2013, 34 : 831 - 832
  • [28] Significance of Akt activation and compartmentalization for prediction of outcome in Her-2 positive breast cancer patients treated with trastuzumab.
    Svoboda, M.
    Grell, P.
    Fabian, P.
    Radova, L.
    Palacova, M.
    Nenutil, R.
    Vyzvla, R.
    BREAST CANCER RESEARCH AND TREATMENT, 2007, 106 : S173 - S173
  • [29] Continued trastuzumab therapy for patients with HER2-positive breast cancer
    Haslbauer, F.
    EJC SUPPLEMENTS, 2008, 6 (07): : 221 - 221
  • [30] TRASTUZUMAB INDUCED CARDIOTOXICITY IN PATIENTS WITH HER2+BREAST CANCER
    Santamaria Elena, Capilla
    Garcia Beatriz, Benitez
    Jose Antonio, Romero Garrido
    Aunon Pilar, Zamora
    Abad Gema, Casado
    del Valle Luis, Gonzalez
    Ambrosio Alicia, Herrero
    ATENCION FARMACEUTICA, 2013, 15 (04): : 261 - 267
12345